Highlights•Immune correlates of protection are guiding HIV-1 vaccine development.•RV144
follow-on trials aim to generate antibody responses to the V1V2 region of Env.•Immunogens …

Animal models have played a pivotal role in all stages of vaccine development. Their
predictive value for vaccine effectiveness depends on the pathogen, the robustness of the …

Novel vaccination approaches based on rational design of B-and T-cell epitopes-epitope-
based vaccines-are making progress in the clinical trial pipeline. The epitope-focused …

The encapsulation of HIV-unrelated T helper peptides into liposomal vaccines presenting
trimers of the HIV-1 envelope glycoprotein (Env) on the surface (T helper liposomes) may …

ABSTRACT A vaccine regimen that elicits broadly neutralizing antibodies (bNAbs) is a major
goal in HIV-1 vaccine research. In this study, we assessed the immunogenicity of the …

To develop a strong HIV specific T-cell response, the HIV-1 Tat and Nef regulatory proteins
have been known as attractive antigenic candidates in vaccine design. A peptide …

Highly active antiretroviral therapy currently used for HIV/AIDS has significantly increased
the life expectancy of HIV-infected individuals. It has also improved the quality of life …

Objectives A potent HIV vaccine should overcome some limitations such as polymorphism of
human HLA, the diversity of HIV-1 virus, and the lack of an effective delivery system. In this …

Blood‐borne viruses, such as hepatitis B virus, hepatitis C virus, human immunodeficiency
virus, and the facultative blood‐borne hepatitis E virus, are considered a major public health …

Cytotoxic T lymphocytes (CTLs) are a critical arm of the immune response to viral infections.
The activation and expansion of antigen specific CTL requires recognition of peptide …